ARP Rheumatology

Página Inicial
Portugal
Lisbon
ARP Rheumatology

The official journal of the Portuguese Society of Rheumatology (). Indexed to PubMed. Both basic research and clinical papers may be submitted.

ARP Rheumatology succeeds Acta Reumatológica Portuguesa, originally founded in 1973 as the official journal of the Portuguese Society of Rheumatology. It is a scientific double-blinded peer-reviewed and open-access journal devoted to progress in the research, diagnosis and treatment of rheumatic and musculoskeletal diseases. The journal aims at serving the interest of both practising clinicians an

d research workers. Editorials, short communications and review articles covering recent developments are included. Controversial techniques and issues on health policy are frequently discussed and serve as tools for encouraging debate. It also concerns about guidelines and clinical protocols related to the practice of rheumatology. The submission has no fees and all articles are available for free.

09/09/2026

💉 Live attenuated vaccination after exposure to TNF inhibitors during pregnancy: reassuring real-world evidence.

The management of live vaccines in infants exposed to TNF inhibitors in utero has evolved following the updated 2024 EULAR recommendations.

In this study, 18 of 29 exposed infants received at least one live attenuated vaccine before 6 months of age. Rotavirus vaccine was given to 17 infants and BCG to 5, including two infants whose mothers had continued adalimumab until weeks 27 and 28 of pregnancy.

✅ No vaccine-related adverse events
✅ No serious infections
✅ No hospitalisations

These real-world findings provide further reassurance regarding the safety of live attenuated vaccination in infants exposed to TNF inhibitors during pregnancy

🔗https://www.arprheumatology.com/article_abstract.php?id=1658

07/09/2026

🦴 X-linked hypophosphataemia (XLH) can remain unrecognised until adulthood and may closely mimic inflammatory arthritis.

In this case, longstanding pain, skeletal deformities and enthesopathy were initially explained by previously undiagnosed XLH. During follow-up, however, the development of symmetrical erosive polyarthritis revealed coexisting seronegative rheumatoid arthritis.

🔎 This case highlights the importance of considering metabolic bone disease in atypical musculoskeletal presentations, while also reassessing the diagnosis when new inflammatory or erosive features appear.

💡 A useful reminder that new symptoms should not always be attributed to an existing underlying disorder.

🔗https://www.arprheumatology.com/article_abstract.php?id=1655

11/08/2026

💊 How common are methotrexate intolerance and liver toxicity in psoriatic arthritis?

Methotrexate (MTX) is the most widely used conventional DMARD in psoriatic arthritis (PsA), but adverse effects can make long-term treatment challenging.

A study of 341 patients found that 26.7% experienced MTX intolerance, while 10.3% developed hepatotoxicity.

Interestingly, the two outcomes showed different clinical patterns. Intolerance was more common among women and was associated with more frequent changes in treatment, whereas hepatotoxicity was more common among men and patients with metabolic comorbidities and treatment-refractory PsA. Arterial hypertension and treatment-refractory disease were independently associated with hepatotoxicity.

Recognising these different profiles may help clinicians optimise monitoring, improve MTX safety, and support treatment persistence.

🔗https://www.arprheumatology.com/article_abstract.php?id=1656

10/08/2026

🆕 A large US study provides new insights into hospitalization outcomes in Sjögren’s syndrome.

Researchers analysed more than 272,000 Sjögren’s syndrome-associated hospitalizations between 2016 and 2020, showing the significant inpatient burden associated with this systemic autoimmune disease.

Although overall in-hospital mortality was lower than in matched controls, patients who developed acute complications faced a substantially greater risk of death. Mechanical ventilation, sepsis, stroke, malignancy and interstitial lung disease were among the strongest predictors of mortality.

The study also identified important inequalities in outcomes, with racial and socioeconomic disparities persisting even after adjustment for other clinical factors.

These findings highlight the importance of recognising Sjögren’s syndrome as a multisystem disease, promptly identifying serious complications, and addressing disparities that may contribute to unequal outcomes

🔗https://www.arprheumatology.com/article_abstract.php?id=1648

06/08/2026

💬 Sexual health is an important part of living well with a rheumatic disease.

Although sexual health has a major impact on quality of life, emotional well-being, and personal relationships, it is still rarely discussed during routine rheumatology care.

This editorial highlights why we need to move beyond focusing only on sexual dysfunction and develop assessment tools that better reflect the real experiences and needs of people living with rheumatic diseases.

By bringing sexual health into everyday clinical care and research, we can provide more holistic, patient-centred care and improve outcomes that truly matter to patients.

Read the editorial and join the conversation about making sexual health a routine part of rheumatology care

🔗https://www.arprheumatology.com/article_abstract.php?id=1651

$Could anifrolumab offer a new treatment option for refractory autoimmune cytopenias in rare interferonopathies?A new cas...$

03/08/2026

Could anifrolumab offer a new treatment option for refractory autoimmune cytopenias in rare interferonopathies?

A new case report describes a patient with spondyloenchondrodysplasia (SPENCD)-associated lupus and transfusion-dependent autoimmune hemolytic anemia who achieved sustained remission after starting anifrolumab.

The article also reviews the current understanding of SPENCD and the growing evidence supporting type I interferon blockade as a targeted, steroid-sparing approach for these challenging conditions.

An important contribution to the evolving field of precision medicine in rare autoimmune diseases.

🔗https://www.arprheumatology.com/article_abstract.php?id=1657

31/07/2026

Can subcutaneous methotrexate improve outcomes and reduce costs in rheumatoid arthritis?

A new study from Portugal suggests the answer is yes.

Researchers found that, compared with oral methotrexate, subcutaneous methotrexate provided better health outcomes while reducing lifetime healthcare costs. Patients gained more quality-adjusted life years, experienced better disease control, required biologic therapies later, and had fewer hospitalizations.

These findings support wider adoption of subcutaneous methotrexate as a cost-effective treatment strategy for rheumatoid arthritis.

📖 Read the full article at https://www.arprheumatology.com/article_abstract.php?id=1652

28/07/2026

📢 New publication in ARP Rheumatology!

This study shows that patients with systemic sclerosis (SSc) who develop small bowel obstruction (SBO) experience significantly worse outcomes than patients with SBO alone, including:
✔️ Higher mortality
✔️ Lower 5-year survival
✔️ More malnutrition and sepsis
✔️ More hospitalisations

These findings reinforce the importance of early diagnosis, close monitoring, and multidisciplinary care for this high-risk group.

Congratulations to all the authors on this important work!

🔗https://www.arprheumatology.com/article_abstract.php?id=1647

07/07/2026

We are pleased to present the latest bibliometric indicators for our journal!

📈 CiteScore 2025: 2.1
🏅 CiteScore Ranking: 55/77 in Rheumatology

📖 2025 Journal Impact Factor (JCR): 1.3
🏅 JCR Ranking: 46/58 in Rheumatology

We sincerely thank our authors, reviewers, editorial board members, readers, and everyone who contributes to the journal.

Your dedication and support are fundamental to our mission of publishing rigorous, clinically relevant, and impactful research in rheumatology.

Together, we remain committed to advancing research and improving lives.

07/07/2026

📊 We are pleased to announce the journal's 2025 CiteScore and ranking:

🔹 CiteScore: 2.1
🔹 Ranking: 55/77 in Rheumatology

We would like to thank all our authors, reviewers, editors, and readers for their invaluable contributions and continued support.

Your commitment is essential to maintaining the quality and impact of ARP Rheumatology.

Together, we remain committed to advancing rheumatology through the publication of high-quality scientific research

Endereço

Avenida Berlim 33
Lisbon
1800-031

Website

http://www.arprheumatology.com/

Notificações

Seja o primeiro a receber as novidades e deixe-nos enviar-lhe um email quando ARP Rheumatology publica notícias e promoções. O seu endereço de email não será utilizado para qualquer outro propósito, e pode cancelar a subscrição a qualquer momento.